Cosmo N.V.
SWXCMHC presents one of the more unusual setups in European pharma right now: earnings momentum is running near multi-year highs while the stock has shed 10% over the past month and is down another 7% this week, sitting at CHF 56.90. The disconnect between fundamentals and price is striking. ORTEX factor scores rank Cosmo's forward EPS momentum in the 91st percentile on a 12-month…
Snapshot as of 19 Aug 2026
CMHC presents one of the more unusual setups in European pharma right now: earnings momentum is running near multi-year highs while the stock has shed 10% over the past month and is down another 7% this week, sitting…
CMHC enters the week under genuine pressure, down 10% over the past month and 7% in the past week alone, with valuation multiples compressing and earnings momentum that has yet to translate into price recovery. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CMHC — free to start on ORTEX.
Sign up for free →Open CMHC on ORTEX